The new hands-free device will offer 420mg of Repatha in a single dose for the patients.

The device, which was developed in partnership with West Pharmaceutical Services, features SmartDose technology platform.

It bonds to the body and patients are hands free during administration.

Patients can carry out moderate physical activities such as walking, reaching or bending, as the 420mg of Repatha is delivered subcutaneously.

Repatha is a human monoclonal antibody, which blocks proprotein convertase subtilisin/kexin type 9 (PCSK9).

The PCSK9 inhibits body's natural system for eliminating bad cholesterol (low-density lipoprotein cholesterol or LDL-C) from the blood.

Repatha received approval in 43 countries, including the US, Japan, Canada and all 28 European Union states.

Amgen research and development executive vice Dr Sean Harper said: "The Pushtronex system exemplifies Amgen's continued innovation and commitment to patients.”

“Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration.

“The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide."

Image: Amgen’s Repatha Pushtronex system. Photo: courtesy of Amgen Inc.